Phaseline

Companies › Tune Therapeutics

Tune Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tune-401
Epigenetic gene silencing therapy
–Phase 1Chronic Hep BJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06671093Tune-401Phase 1Chronic Hep BInfectious diseaseJun 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.